Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141947
Status:
UNKNOWN
Last Update Posted:
2013-07-24
First Post:
2005-09-01
Brief Title:
Bexarotene Treatment in Schizophrenia
Sponsor:
Beersheva Mental Health Center
Organization:
Beersheva Mental Health Center
Study Overview
Official Title:
Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients An Open Label Trial
Status:
UNKNOWN
Status Verified Date:
2005-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this proposed study we aim to investigate the effects of Bexarotene Targretin LGD1069 4-1-5678-tetrahydro-35588-pentamethyl-2-naphthalenyl ethenyl benzoic acid on severity of psychopathology cognitive impairment and quality of life in schizophrenia patients in an open label trial The rationale behind add-on oral bexarotene to ongoing antipsychotic treatment in schizophrenia patients is based on both the retinoid dysregulation hypothesis Goodman 1995 and the growth factors deficiency and synaptic destabilization hypothesis Moises et al 2002 of schizophrenia In this clinical trial a novel regimen of low dose bexarotene Targretin 75 mgday will be added for 6 weeks to the standard treatment of 15 schizophrenia patients on stable antipsychotic treatment Participants will be assessed at baseline and after 2 4 and 6 weeks of treatment A battery of research instruments will be used for assessment of efficacy and safety psychopathology and side effects In addition cholesterol and triglyceride levels liver and thyroid function tests and a blood cell count will be monitored at baseline and during therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None